Navigation Links
NIH expands key pharmacogenomics resource
Date:9/7/2010

To help advance research on how genes affect responses to medicines, the National Institutes of Health is spending $15 million over five years to expand a key resource, the Pharmacogenomics Knowledge Base (PharmGKB), http://www.pharmgkb.org/ .

The goal of pharmacogenomics is to use information about a patient's genetic make-up to optimize his or her medical treatment. As the field has grown, so has PharmGKB. Begun in 2000 to catalog links between human genetic variation and drug responses, the PharmGKB Web site is now a centralized hub that collects, analyzes and integrates data for national and international research consortia. All information in PharmGKB is carefully curated, meaning it is annotated and cross-referenced with related research data.

"PharmGKB is a trusted source for curated knowledge about pharmacogenomics," said Jeremy M. Berg, director of the National Institute of General Medical Sciences (NIGMS), which administers the PharmGKB grant. "It plays a critical role in moving us closer to the goal of personalized prescriptions, meaning each patient receives a safe and effective drug dose based on his or her individual characteristics."

PharmGKB, which is freely available to the scientific community, identifies biochemical pathways influenced by specific drugs and provides detailed summaries of key genes that influence a person's response to a broad array of medicines. PharmGKB also includes six staff scientists and six software engineers who conduct research, collaborate with other investigators and build the software infrastructure supporting PharmGKB.

In a 2009 study PharmGKB researchers, together with scientists from Europe, Asia, South America and the Middle East, were able to utilize patients' genetic information to better predict their optimal doses of warfarin, a widely used blood thinner that is tricky to dose. The concept of using genotyping in this way is now being tested in a large-scale clinical trial sponsored by the NIH's National Heart, Lung, and Blood Institute.

PharmGKB and other scientists also analyzed a person's entire genome, to identify variations associated with disease risk and adverse drug reactions.

During the next five years, PharmGKB plans to:

  • Develop tools that automatically extract information from the biomedical literature and key databases.

  • Intensify its focus on understanding the molecular basis for drug toxicity and multiple-drug interactions, information that may help improve the safety and efficacy of medicines.

  • Analyze the genomes of additional individuals, including a family that has volunteered to be studied.

  • Develop guidelines for doctors about the use of genetic tests to customize dosages when prescribing certain medicines.

"PharmGKB has become a powerful resource not only by providing high-quality information, but also by bringing researchers together to share ideas and collaborate," said Rochelle M. Long, Ph.D., who directs pharmacogenomics research programs at NIGMS. "We anticipate that such collaborations will continue to grow for the next five years."

PharmGKB is part of a broader NIH pharmacogenomics initiative that includes individual research projects and a nationwide research consortium, the NIH Pharmacogenomics Research Network (PGRN). New PGRN grants are also being announced at this time.


'/>"/>

Contact: Alisa Zapp Machalek
alisa.machalek@nih.gov
301-496-7301
NIH/National Institute of General Medical Sciences
Source:Eurekalert

Related biology news :

1. Core knowledge of tree fruit expands with apple genome sequencing
2. High-resolution imaging expands vision research of live birds of prey
3. Orbel Expands Fabric over Foam Gasket Product Line
4. HIV vaccine strategy expands immune responses
5. Identive Group Expands Executive Management Team
6. Identive Group Expands Executive Management Team
7. Nepal expands critical tiger habitat
8. ID Analytics Expands Availability of On-Demand Identity Intelligence Solutions for the Government Market
9. Fujitsu Expands Support for Ethernet Networks With New Additions to XG Switch Product Line
10. NIH expands Human Microbiome Project; funds sequencing centers and disease projects
11. Fetal alcohol syndrome testing expands
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... -- In vitro diagnostic (IVD) companies were very active in ... Kalorama Information expects that trend to continue – though ... uncertainty in reimbursement and healthcare reform in ... acquisitions landscape. Instead of looking to buy technology, the ... of their home country and also to increase their ...
(Date:1/12/2017)... , January 12, 2017 A new report by Allied Market ... the global biometric technology market is expected to generate revenue of $10.72 billion by ... Continue Reading ... Allied Market Research Logo ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
(Date:1/6/2017)... Jan. 5, 2017  Delta ID Inc., a leader ... technology for automotive at CES® 2017. Delta ID has ... to demonstrate the use of iris scanning as a ... the driver in a car, and as a way ... experience. Delta ID and Gentex will demonstrate ...
Breaking Biology News(10 mins):
(Date:1/21/2017)... 21, 2017   Boston Biomedical , an industry ... target cancer stemness pathways, today presented data from two ... the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal ... In a Phase Ib/II study of ... inhibit cancer stemness pathways by targeting STAT3 – colorectal ...
(Date:1/20/2017)... , ... January 20, 2017 ... ... Less Exposure Surgery (LES®) Technologies, announced today the next evolution in spinal ... Screw System platform). In contrast to the competition, SpineFrontier is focused on ...
(Date:1/19/2017)... Research and Markets ... has announced the addition of the ... 2025" report to their offering. Report ... provides a detailed analysis on current and future market trends to identify ... market values as the base numbers Key market trends ...
(Date:1/19/2017)... AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: AQB), ... and a majority-owned subsidiary of Intrexon Corporation (NYSE: ... listing of its common shares on the NASDAQ Stock ... "AquaBounty,s listing on NASDAQ represents an important milestone ... the U.S. markets as we advance plans for commercial ...
Breaking Biology Technology: